Antibodies approved for the treatment of selected cancers based on interaction of PD-L1 include Atezolizumab, used in RCC and NSCLC, Durwalumab, used in mUC and NSCLC., and Awelumab for the treatment of Merkel-cell carcinoma (MCC) and mUC [42]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.